At Cardiology Associates of Green Bay, our providers are dedicated to participate in research studies that may lead to improvements in the quality and quantity of our patient's lives. We offer our patients the opportunity to participate in clinical trials if they fit the criteria for clinical studies. We understand that this an important medical decision. Participating in research (or choosing not to) will never affect the quality of care provided by our group. Our providers and research staff are here to answer any questions that you may have. The research office phone number is 920-617-2060.

Currently Actively Enrolling Research Studies:

Improve It Study: compares Vytorin® to Simvastatin in patients after they suffer a heart attack or have unstable angina. This study compares two drugs, Ezetimibe/Simvastatin Combination 10/40mg (sold as Vytorin®) and Simvastatin 40mg (sold as Zocor®). The goal is to determine how well each of these drugs can lower LDL-C ("bad" cholesterol) levels and how this leads to better clinical outcomes.

Aristotle Study: This study compares Apixaban to Warfarin. This study will evaluate the safety and efficacy of Apixaban as compared to warfarin in preventing stroke and systemic embolism in subjects with atrial fibrillation

Dal-outcomes: This study is looking at a novel medication named dalcetrapib designed to raise your HDL or "good" cholesterol. The purpose of this study is to learn if dalcetrapib will reduce the risk of death from cardiovascular disease or having another cardiovascular event such as a myocardial infarction (heart attack), stroke (brain attack), revascularization procedures (angioplasty, implanting a stent) or hospitalization for acute coronary syndrome (chest pain not associated with physical exertion and electrocardiogram [ECG] abnormalities). Dalcetrapib, is a drug which is under investigation and considered experimental. Experimental means that it has not yet been approved by regulatory authorities.

Durability II: The purpose of this study is to collect information and to find out if the use of the EverFlex Stent is more safe and effective than angioplasty when used in the leg above the knee. Participants in this study will have a narrowing in your superficial femoral artery that may also extend into your popliteal artery. These arteries are located between your hip and knee.

Optimum Registry: This registry is a five year follow open to all patients who receive a St. Jude Medical Optimum lead as part of a pacemaker.